Skip to main content
. 2022 Oct 17;40(34):3965–3974. doi: 10.1200/JCO.22.01207

FIG 2.

FIG 2.

Kaplan-Meier curves of the OS of patients according to treatment arm (arm 3 with bevacizumab concurrent-maintenance, v arm 1 with placebo) in patients with unfavorable or favorable KELIM (KEL) score, in the whole population. HR, hazard ratio; KELIM, ELIMination rate constant K; mPFS, median PFS (months); PFS, progression-free survival; Ref, reference.